There is strong demand for compassionate use of OST-HER2 from the patient community, underscoring the urgent need for new therapies in Human Metastatic Osteosarcoma.” — Paul Romness, MPH, Chairman & ...
We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST-HER2 for pediatric cancer patients with osteosarcoma.” — Paul Romness, MPH, Chairman & CEO of ...
NEW YORK, NY, UNITED STATES, February 2, 2026 /EINPresswire.com/ — OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results